Among women worldwide, cervical cancer is the second-most common cancer, and cervical smears and DNA detection have low sensitivity or are too expensive. The concentrations of carcinoembryonic antigen (CEA) and squamous cell carcinoma (SCC) in the serum were detected using a sandwich immunoassay. The CEA and SCC in the serum were captured by anti-CEA and anti-SCC antibodies. After combining other anti-CEA- and anti-SCC-labeled antibodies with europium (III) (Eu ) and samarium (III) (Sm ) chelates, CEA and SCC were detected with time-resolved fluorometry (TRF). The linear correlation coefficients (R ) of the CEA and SCC standard curves were 0.9997 and 0.9997, respectively. The minimum detection level for CEA was 1.15 ng/mL (the linear dynamic range was 3.24-543.67 ng/mL), and the average recovery was 100.83%. The sensitivity for SCC detection was 0.54 ng/mL (the linear dynamic range was 2.47-96.58 ng/mL), and the average recovery was 101.02%. High R between the results of commercial assays and this method were obtained (R = 0.9983 for CEA, R = 0.9878 for SCC). These findings indicated that the dual-label TRFIA invented in this study has high sensitivity, accuracy, and specificity in clinical analysis, which indicates that this method could be used for the early diagnosis and follow-up surveillance of cervical cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bab.1663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma.
Front Oncol
December 2024
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Article Synopsis
- Patients with lung squamous cell carcinoma (LUSC) show limited benefits from targeted therapies, but immunotherapy, particularly PD-1 inhibitors, has emerged as a potential treatment option, although responses vary among individuals.
- A study analyzed data from 212 LUSC patients undergoing PD-1 combination therapy, focusing on making sense of various hematological indices at different treatment stages to find predictors for treatment outcomes and survival analysis.
- Findings revealed specific hematological markers (like SCC and NSE levels) significantly correlate with progression-free survival (PFS) and overall survival (OS), suggesting their potential as independent indicators for predicting patient prognosis in LUSC.
Assessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study.
J Thorac Dis
November 2024
Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Background: There is uncertainty with respect to the baseline tumor markers and clinical outcomes for patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The study aimed to assess the association between baseline tumor markers and progressive pulmonary fibrosis (PPF) and prognosis.
Methods: This is a prospective cohort study.
Efficacy of total laparoscopic hysterectomy without uterine manipulators in patient with early-stage cervical cancer.
Pak J Med Sci
November 2024
Shifen Dai, Department of Gynecology, Meizhou People's Hospital, Meizhou, Guangdong Province 514000, P.R. China.
Article Synopsis
- The study assessed the feasibility and safety of performing total laparoscopic hysterectomy (TLH) without using a uterine manipulator in 72 patients with early-stage cervical cancer from January 2018 to December 2020.
- Results showed that both groups experienced a significant decrease in tumor marker levels after surgery, with the group that did not use the uterine manipulator showing even lower levels postoperatively.
- Over a three-year follow-up, there were no notable differences in postoperative complications or survival rates between the two groups, indicating that the uterine manipulator is not necessary for safe and effective TLH in such patients.
Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.
Clin Chim Acta
January 2025
Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address:
Article Synopsis
- The study investigated the potential of the abnormal glycan structure Siaα-2,6Gal for diagnosing lung cancer early and differentiating it from other conditions.
- Clinical data and serum samples were analyzed from 730 lung cancer patients and 120 healthy individuals, measuring various serum markers including Siaα-2,6Gal and traditional tumor markers.
- Results showed that Siaα-2,6Gal levels were significantly higher in lung cancer patients, especially in early-stage cases, indicating it may serve as a more effective biomarker than traditional tests for diagnosing lung cancer.*
Development and validation of a tumor marker-based model for the prediction of lung cancer: an analysis of a multicenter retrospective study in Shanghai, China.
Front Oncol
October 2024
Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background: The incidence and mortality rates of cancer are the highest globally. Developing novel methodologies that precisely, safely, and economically differentiate between benign and malignant lung conditions holds immense clinical importance. This research seeks to construct a predictive model utilizing a combination of diverse biomarkers to effectively discriminate between benign and malignant lung diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!